195 related articles for article (PubMed ID: 16216470)
1. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.
Soontornpas C; Saraya S; Chulasiri M; Chindavijak B; Mootsikapun P
Int J Antimicrob Agents; 2005 Nov; 26(5):403-7. PubMed ID: 16216470
[TBL] [Abstract][Full Text] [Related]
2. Use of a low-dose steroid as an adjunct in the treatment, in mice, of severe sepsis caused by Burkholderia pseudomallei.
Panomket P; Chetchotisakd P; Sermswan RW; Pannengpetch P; Wongratanacheewin S
Ann Trop Med Parasitol; 2009 Oct; 103(7):635-46. PubMed ID: 19825285
[TBL] [Abstract][Full Text] [Related]
3. Activity of tigecycline in the treatment of acute Burkholderia pseudomallei infection in a murine model.
Feterl M; Govan B; Engler C; Norton R; Ketheesan N
Int J Antimicrob Agents; 2006 Nov; 28(5):460-4. PubMed ID: 17046208
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
Br J Clin Pharmacol; 2000 Aug; 50(2):184-91. PubMed ID: 10930972
[TBL] [Abstract][Full Text] [Related]
5. Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters.
Huffam S; Jacups SP; Kittler P; Currie BJ
Trop Med Int Health; 2004 Jun; 9(6):715-7. PubMed ID: 15189462
[TBL] [Abstract][Full Text] [Related]
6. Why is the response rate slow in ceftazidime therapy for melioidosis?
Puthucheary SD; Sam IC
Expert Rev Anti Infect Ther; 2012 Jan; 10(1):5-7. PubMed ID: 22149608
[No Abstract] [Full Text] [Related]
7. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion.
Piccoli L; Larosa M; Marchetti F
J Antimicrob Chemother; 2003 Dec; 52(6):1047-8. PubMed ID: 14585860
[No Abstract] [Full Text] [Related]
8. Severe community-acquired pneumonia and sepsis caused by Burkholderia pseudomallei associated with flooding in Puerto Rico.
Christenson B; Fuxench Z; Morales JA; Suárez-Villamil RA; Souchet LM
Bol Asoc Med P R; 2003; 95(6):17-20. PubMed ID: 15449787
[TBL] [Abstract][Full Text] [Related]
9. Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials.
Karunakaran R; Puthucheary SD
Scand J Infect Dis; 2007; 39(10):858-61. PubMed ID: 17852912
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.
Angus BJ; Smith MD; Suputtamongkol Y; Mattie H; Walsh AL; Wuthiekanun V; Chaowagul W; White NJ
Br J Clin Pharmacol; 2000 May; 49(5):445-52. PubMed ID: 10792202
[TBL] [Abstract][Full Text] [Related]
11. Melioidosis: advances in diagnosis and treatment.
Cheng AC
Curr Opin Infect Dis; 2010 Dec; 23(6):554-9. PubMed ID: 20847695
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary Delivery of Ceftazidime for the Treatment of Melioidosis in a Murine Model.
Ruiz SI; Bowen LE; Bailey MM; Berkland C
Mol Pharm; 2018 Mar; 15(3):1371-1376. PubMed ID: 29363975
[TBL] [Abstract][Full Text] [Related]
13. Cases of melioidosis in a university teaching hospital in Malaysia.
Raja NS
J Microbiol Immunol Infect; 2008 Apr; 41(2):174-9. PubMed ID: 18473106
[TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Harris P; Engler C; Norton R
Int J Antimicrob Agents; 2011 Jun; 37(6):547-9. PubMed ID: 21481571
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of Clinical Isolates of
Sengyee S; Saiprom N; Paksanont S; Limmathurotsakul D; Wuthiekanun V; Chantratita N
Am J Trop Med Hyg; 2017 Jul; 97(1):62-67. PubMed ID: 28719324
[No Abstract] [Full Text] [Related]
16. Prevalence of bla(PenA) and bla(OXA) in Burkholderia pseudomallei Isolated from Patients at Sappasitthiprasong Hospital and Their Susceptibility to Ceftazidime and Carbapenems.
Panya M; Thirat S; Wanram S; Panomket P; Nilsakul J
J Med Assoc Thai; 2016 Jan; 99 Suppl 1():S12-6. PubMed ID: 26817233
[TBL] [Abstract][Full Text] [Related]
17. Serum bactericidal and inhibitory titres in the management of melioidosis.
Simpson AJ; Dance DA; Wuthiekanun V; White NJ
J Antimicrob Chemother; 2000 Jan; 45(1):123-7. PubMed ID: 10629024
[TBL] [Abstract][Full Text] [Related]
18. Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.
LaRosa SP; Opal SM; Utterback B; Yan SC; Helterbrand J; Simpson AJ; Chaowagul W; White NJ; Fisher CJ
Int J Infect Dis; 2006 Jan; 10(1):25-31. PubMed ID: 16290015
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility patterns of Burkholderia pseudomallei among melioidosis cases in Kedah, Malaysia.
Hassan MR; Vijayalakshmi N; Pani SP; Peng NP; Mehenderkar R; Voralu K; Michael E
Southeast Asian J Trop Med Public Health; 2014 May; 45(3):680-8. PubMed ID: 24974653
[TBL] [Abstract][Full Text] [Related]
20. Melioidotic osteomyelitis treated with antibiotic-calcium hydroxyapatite composite: case report with four-year follow-up.
Ng WM; Kwan MK; Merican AM
Singapore Med J; 2006 Jan; 47(1):71-4. PubMed ID: 16397726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
